Articles tagged with Breast Cancer
Research reveals tamoxifen boosts PI3K signaling, potentially increasing uterine cancer risk in breast cancer patients. Preclinical studies show PI3K inhibitor alpelisib mitigates this effect.
Researchers at Weill Cornell Medicine are studying breast cancer as a series of inflection points to identify potential intervention points and develop therapeutics for triple negative breast cancer. The goal is to create a large repository of organoids from tissue samples to study gene expression, epigenetic changes, and immune response.
A recent study found that patients with hormone receptor-positive breast cancer who experience rising ESR1 mutations before disease progression can benefit from an early switch to fulvestrant plus palbociclib. This approach yields a statistically and clinically significant gain in progression-free survival, potentially justifying its a...
A recent study has found that Black women are significantly more likely to develop lymphedema following breast cancer treatment compared to white women. The study, which analyzed data from 304 breast cancer patients, also found that Hispanic women had a higher risk of developing the condition.
Researchers discovered that the SET2,3 index provides complementary prognostic information about breast cancer outcomes, particularly for patients with hormone receptor-positive breast cancer. The study suggests that using both clinical and molecular information from a patient's tumor can guide treatment decision-making.
A recent study found that pathologic complete response rates did not differ by racial groups, but HR-positive/HER2-negative breast cancer showed a significant survival disparity between Black and white women. The study suggests that tumor molecular subtype is a more significant factor in breast cancer survival than race.
Patients treated with pyrotinib plus capecitabine had a lower risk of death and longer progression-free survival compared to those receiving lapatinib plus capecitabine. Pyrotinib is an irreversible tyrosine kinase receptor inhibitor targeting HER2, EGFR, and HER4.
Researchers discovered that pregnancy triggers the activation of Natural Killer T (NKT) cells to prevent breast cancer. After pregnancy, breast epithelial cells produce a specific protein called CD1d, which attracts NKT cells to monitor and eliminate potential cancer cells.
The study used multigene sequencing to identify genomic alterations in patients with metastatic breast cancer. Patients with genomic alterations ranked as ESCAT I/II saw improved progression-free survival with targeted therapies matched to their genomic changes, while those without these alterations did not benefit from the treatment.
In a phase III trial, elacestrant showed significant benefits in decreasing death or disease progression and increasing progression-free survival compared to standard of care. The treatment was well-tolerated with manageable side effects, offering hope for patients with ER-positive/HER2-negative metastatic breast cancer.
Researchers used imaging mass cytometry to analyze protein expression and cell location in tumor samples. High density of antigen-presenting cells with high PD-L1 and IDO expression was associated with higher pathological complete response rate in patients treated with atezolizumab plus chemotherapy.
Investigators at Weill Cornell Medicine identified significant age-related differences in tumor characteristics across various cancers, suggesting potential for personalized treatment approaches. They found that tumors from younger patients showed advanced signs of aging and more mutations associated with aggressive disease.
Women with breast implants after mastectomy are at high risk of developing cardiovascular disease due to chemotherapy and radiation. Inaccuracies in cardiac imaging studies, such as echocardiography and nuclear tests, have been reported in some cases.
A study found that racial disparities in mammography screening worsened after COVID-19 closures, with non-white patients facing reduced access to facilities. Early interventions aimed at expanding access to these facilities helped to recover late recovery volumes for patients of races other than white.
Moffitt researchers have developed a HER3-specific dendritic cell cancer vaccine that delays tumor growth and prolongs survival in mouse models. The vaccine targets the HER3 protein, which is involved in the growth and spread of many different cancer types.
A Michigan Tech-developed machine learning model uses probability to classify breast cancer shown in histopathology images and evaluate the uncertainty of its predictions. The model outperforms similar models and can measure uncertainty, promising time savings and referrals to human experts.
A large clinical trial has found that postmenopausal women with hormone receptor-positive, HER2-negative breast cancer and a 21-gene recurrence score of 25 or lower can safely skip chemotherapy. In contrast, premenopausal patients with positive nodes and low RS scores benefit from chemotherapy.
A new diagnostic tool for breast cancer uses a low-voltage electrical current to detect changes in lymphatic interstitial fluid, showing 70% effectiveness in predicting cancer presence. The device can be used repeatedly on women of any age, providing an additional diagnostic option for younger patients and those with dense breast tissue.
The AACR and Pelotonia launch a grants program to recognize five influential female researchers in breast and gynecologic cancers. Nomination deadlines are January 14, 2022, with awards presented at the AACR Annual Meeting 2022.
Researchers at Princeton University have discovered a new compound that can disable the MTDH gene, which is essential for cancer progression and metastasis. The compound shows promise in treating major human cancers, including breast, prostate, lung, and colon cancers.
Researchers found that tumor cells contribute differently to metastases and therapy resistance depending on their EMT status. Partial EMT breast cancer cells act as pioneer cells leading collective cell migration and promote lung metastases, while full EMT cells rarely appear in metastases.
Researchers have discovered a new therapeutic approach that prevents the growth of metastatic tumors in mice by forcing cancer cells into a dormant state. The drug C26 activates NR2F1, a protein that can induce cancer cell dormancy and prevent recurrence and metastasis.
A modeling study found that annual mammography screening beyond age 75 may provide little to no benefit in terms of lives saved, while increasing costs and potential harms from overdiagnosis. Biennial screening up to age 80 is more cost-effective but yields a small number of deaths averted.
Researchers at the University of Helsinki and Aalto University have developed a gel-grown mini-breast cancer model that can effectively treat hormone-dependent breast cancers. The discovery opens new avenues for hormonal therapies, individual drug responses, and drug resistance mechanisms.
A fraction of patients with high dihydrolipoamide S-Succinyltransferase (DLST) expression in their tumor cells may benefit from CPI-613, a drug targeting the TCA cycle. DLST plays a crucial role in TNBC pathogenesis, and its expression could serve as a biomarker for targeted therapy.
Women with breast cancer are at a higher risk of developing atrial fibrillation and dying from heart-related issues within the first year. The condition was more common in women who did not receive surgery or radiation as their initial treatment.
A new study found that tumors with one mutant copy of the PIK3CA gene tend to have lower PI3K activity, while those with two or more copies often have higher PIK3α activity, leading to more aggressive tumors and poorer prognosis. The research also discovered a counterintuitive relationship between PI3K mutations, PI3K activity, and ste...
This study found that aerobic exercise enhances doxorubicin's ability to kill cancer cells while minimizing its toxic effects on the heart. In addition, exercise has been shown to reduce the risk of breast cancer recurrence and improve quality-of-life parameters in cancer patients.
A UArizona Health Sciences study found that American Indian and Alaska Native women with early-stage breast cancer had a higher percentage of mastectomy and a lower percentage of lumpectomy compared to white women. The study suggests that geographic and socioeconomic factors may contribute to these disparities.
A study published in The BMJ found that early post-operative exercise improves shoulder and arm mobility, reduces pain, and increases quality of life for women after non-reconstructive breast cancer surgery. The exercise programme is also cost-effective, with an average saving of £387 per patient.
A Johns Hopkins-led study found that leptin cancels out the effects of Tamoxifen, making it ineffective for obese patients with breast cancer. Researchers suggest that interventions targeting leptin or Med1 may improve Tamoxifen's success in this group.
Researchers discovered melatonin's antitumor effects in gallbladder cancer cells, promoting ROS-mediated apoptosis and suppressing the PI3K/Akt/mTOR signaling pathway. The study suggests melatonin as a potential novel candidate for gallbladder cancer treatment.
A study analyzing 93 precision oncology studies revealed significant underrepresentation of racial and ethnic minority populations in cancer research. These disparities affect the representation of diverse patient groups in clinical trials, which can impact treatment efficacy and outcomes.
Research reveals that cancer cells have softer membranes than normal cells, but stiffening them can prevent abnormal changes in structure and motility. Stiffened breast cancer cells lost the ability to spread to the lungs in mouse experiments, suggesting a potential strategy for cancer treatments.
According to experts, half of patients with two common subtypes of advanced breast cancer may live for five years or longer. The new guidelines also aim to improve treatment options for triple-negative breast cancer patients.
Researchers found that combining selinexor with olaparib induces robust anti-tumor activity in vitro and in vivo in triple negative breast cancer cell lines. The combination therapy overcomes the poor prognosis associated with TNBC, characterized by low disease-free and overall survival rates.
COVID-19 vaccinations have been shown to be safe for advanced breast cancer patients, with no notable differences between vaccine brands. The second dose is crucial to induce an immune response, which has been found in 80% of patients with solid tumours.
A recent survey of advanced breast cancer patients in the UK reveals that only 14% have been recruited to a trial, highlighting a need for improved access. Patients often face barriers, including clinician reluctance to discuss trials and a lack of patient-friendly databases.
A team of researchers at George Washington University has identified DDR1 as a key molecule that prevents immune cells from entering and killing breast tumor cells. Deactivating this molecule allows immune cells to infiltrate the tumor and kill cancer cells, opening up new avenues for therapeutic agents.
A major global study found that the risk of breast cancer spreading to other parts of the body ranges from 6% to 22%. Younger women and those diagnosed with larger tumours face a higher risk. The study also sheds light on how many people develop advanced breast cancer, a gap in knowledge until now.
Researchers in mice found that chemotherapy enhances cancer's spread by making blood vessel walls more receptive, allowing cancer cells to latch on. The study shows how a chemo drug like cyclophosphamide alters non-cancer cells' properties, facilitating the cancer cells' attachment and progression.
A new study improves AI diagnoses by penalizing algorithms for false negatives, which can be more urgent than accuracy. Researchers achieved significant improvements in precision and recall for chronic kidney disease and other conditions using cost sensitivity techniques.
Researchers at Boston University have developed a new online risk prediction model for breast cancer in Black women, suitable for use in primary care settings. The model is well-calibrated and discriminatory accurate, with the highest accuracy for women under age 40.
A genetic signature has been discovered that can identify drivers of poor outcomes in advanced estrogen-receptor positive (ER+) breast cancer. The signature detects the presence of mutations and translocations in the ER gene that confer tumor independence from estrogen, making it resistant to current therapies.
Researchers at the University of Alabama at Birmingham have developed a method to identify non-responding tumors using hypoxia imaging, which shows promise for improving response rates. Investigational new drug evofosfamide was found beneficial in treating hypoxic tumors with immunotherapy.
Researchers from Kazan Federal University have developed a gene-cell preparation that uses membrane vesicles to target and kill cancer cells. The technology has shown promise in treating various types of cancer, including breast, lung, and colon cancer.
Researchers have opened a novel study for a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease. The phase I trial will determine the maximum tolerated dose of the vaccine in patients with early-stage triple-negative breast cancer.
A new study finds that high-dose radiation therapy can lengthen progression-free survival for people with advanced lung cancer when systemic therapy has not fully halted tumor growth or spread. Stereotactic body radiation therapy (SBRT) shows promise in treating oligoprogressive, metastatic lung and breast cancer.
A new study found that surgery benefits men with Stage IV breast cancer, particularly those responsive to systemic therapy. Trimodal therapy, including surgery and radiation, shows improved 5-year overall survival rates compared to systemic therapy alone.
A new, bacteria-based system can detect cancer cells and release therapeutic drugs directly into them, leaving healthy cells intact. The technology has shown promising results in preclinical tests on mice, particularly for liver cancer.
Researchers have trained a neural network to detect anomalies in medical images, adapting it to the nature of medical imaging and achieving better results. The new method uses weakly supervised training and can spot small-scale anomalies, accelerating the work of histopathologists and radiologists.
A study published in Psycho-Oncology found that breast cancer patients with low resilience are more likely to experience depressive symptoms and poor health-related quality of life during chemotherapy. Patients with high resilience, on the other hand, were less likely to develop depression and reported better health outcomes.
Women with dense breast tissue are at increased risk of developing breast cancer, which can be masked by mammograms. Mayo Clinic expert Suneela Vegunta recommends supplemental screening to diagnose additional cancers; however, consensus-based guidelines and randomized controlled studies are needed.
The new ESMO Clinical Practice Guideline provides comprehensive guidance on diagnosing, staging, and treating patients with metastatic breast cancer. The guideline incorporates recent clinical trial data to inform treatment choices, taking into account tumour biology and emerging targeted therapies.
Researchers at the University of Notre Dame discovered that aging breast tissue can lead to increased invasiveness-related gene expression in normal epithelial cells. This finding suggests that a decline in extracellular matrix composition and structure may contribute to the development of invasive breast cancer.
Researchers developed a new treatment for breast cancer by targeting the nervous system around the tumor. Cancer cells recruit nerve cells to aid their growth and proliferation, but the new treatment paralyzes these nerves and disconnects them from cancer cells.
Researchers developed a compact photonic resonator absorption microscope for point-of-care diagnostics, using photonic crystal biosensors to detect proteins or other biomarkers linked to gold nanoparticles. The portable instrument costs $7,000 and has potential applications in detecting various cancers.
Researchers found that aggressive triple-negative breast cancer cells use swiprosin-1 to hijack a cellular conveyor belt, increasing integrin circulation and cell migration. High swiprosin-1 expression correlates with metastasis formation and malignancy in breast cancer.
Physician attitudes and beliefs contribute to racial disparities in referrals for genetic counseling and testing. Black women are less likely to be referred for these services, despite having a higher breast cancer mortality rate than white women.
Researchers at the University of Copenhagen have discovered that the BRCA2 gene requires a specific enzyme, PP2A-B56, to repair DNA damage. This finding may pave the way for more targeted treatment of cancer patients with certain mutations.